Dr. King has spent the last two decades pursuing her passion for turning innovative science into effective treatments for disease. She came to Mnemosyne from Amgen, where she led East Coast business development and external venture innovation, following Amgen's acquisition of deCODE genetics in December 2012. That deal was the culmination of Dr. King's tenure at deCODE, where she headed business development as part of the founding turnaround team. Her other roles have been similarly focused at the intersection of leading edge science and cures for patients; Dr. King headed up Scientific and Strategic Operations globally at the Novartis Institutes for Biomedical Research, and served as VP Business Development and Strategy at both the J. Craig Venter Institute and PerkinElmer Life and Analytical Sciences, after starting her career as a consultant for McKinsey & Company. She obtained her PhD in Molecular Genetics from Trinity College, University of Cambridge and her AB Phi Beta Kappa in Molecular Biology from Princeton University.